Venus Remedies Limited stock analysis
Want to see IN:VENUSREM full AI Analyst Report?
Venus Remedies Limited (VENUSREM) Stock Price & Analysis
VENUSREM Stock Chart & Stats
- Day’s Range
- INR 1,445.45 - INR 1,522.00
- 52-Week Range
- INR 553.45 - INR 2,043.15
- Previous Close
- INR 1,521.50
- Volume
- N/A
- Average Volume (3M)
- 3,882
- Market Cap
- INR 19.37B
- Enterprise Value
- INR 23.23B
- Total Cash (Recent Filing)
- INR 901.50M
- Total Debt (Recent Filing)
- INR 117.40M
- Price to Earnings (P/E)
- 16.0
- Beta
- 0.93
- Next Earnings
- Feb 14, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Aug 07, 2026
- Dividend Yield
- 0.69%
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Positive revenue growth across the latest three reported years indicates renewed demand and commercial traction after the 2023 decline. Continued top-line expansion can support operating scale, strengthen market reach, and provide a durable base for future earnings growth.
Profitability Improvement
The sharp increase in net income and EBIT demonstrates substantial operating improvement in the latest period. If the stronger earnings level is maintained, it should improve internal funding capacity, support reinvestment in products, and enhance resilience across the business cycle.
Balance Sheet Strength
Very low leverage and steadily expanding equity give Venus Remedies meaningful financial flexibility. A conservative capital structure reduces dependence on external financing, helps absorb operating volatility, and leaves greater capacity to fund growth or manage unexpected pressure.
Bears Say
Margin Visibility
Material gross-margin swings make it harder to determine how much of the latest profit surge reflects durable operating improvement. Without clear evidence that margins remain elevated, future earnings could be less predictable and the current profitability level may be difficult to sustain.
Cash Flow Variability
Although recent cash generation improved, uneven conversion from earnings into operating cash flow indicates working-capital or investment-cycle variability. This can make internally generated funding less consistent and may complicate decisions on expansion, debt reduction, or shareholder returns.
Debt Volatility
Low leverage limits immediate balance-sheet risk, but changing absolute debt levels indicate that financing needs have not been completely stable. Further increases could raise interest obligations or reduce flexibility, particularly if profit margins or cash conversion weaken.
Venus Remedies Limited News
VENUSREM FAQ
What was Venus Remedies Limited’s price range in the past 12 months?
What is Venus Remedies Limited’s market cap?
When is Venus Remedies Limited’s upcoming earnings report date?
How were Venus Remedies Limited’s earnings last quarter?
Is Venus Remedies Limited overvalued?
Does Venus Remedies Limited pay dividends?
What is Venus Remedies Limited’s EPS estimate?
How many shares outstanding does Venus Remedies Limited have?
What happened to Venus Remedies Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Venus Remedies Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Venus Remedies Limited
Venus Remedies Limited is a pharmaceutical enterprise engaged in the development, production, and global distribution of its medicinal products, serving both the Indian and international markets. The company's diverse portfolio addresses a wide spectrum of therapeutic areas, including treatments for pain and fever, diabetes, bacterial infections, cardiovascular conditions, gastrointestinal disorders, neurological ailments, and oncology. Additionally, it provides solutions for respiratory health, skin and wound care, stress management, and urological issues, alongside essential vitamins, minerals, and nutritional supplements. Venus Remedies is also active in the field of antimicrobial resistance, offering specialized products, and it supplies disinfectants and hand sanitizers. Furthermore, the firm maintains a distinct line of herbal products and offers hormones and iron supplements. Established in 1989, Venus Remedies Limited operates from its headquarters in Panchkula, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ashutosh Jain
- Employees
- 1,472
- Website
- www.venusremedies.com
- Address
- Plot 51-52, Industrial Area, Panchkula, HA, 134113, IN
Venus Remedies Limited (VENUSREM) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 5 | 10 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 3 | 0 | 9 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:INDOCOIndoco Remedies Limited | ||
| IN:INDSWFTLABInd-Swift Laboratories Ltd. | ||
| IN:LINCOLNLincoln Pharmaceuticals Ltd | ||
| IN:SYNCOMFSyncom Formulation (India) Ltd. | ||
| IN:WINDLASWindlas Biotech Ltd. |










